Alpenglow unveils a $50,000 research grant program for novel applications of its brand new 3D I/O Pro assay. Unlock insights into the tumor microenvironment with whole tissue 3D imaging and analysis.

We have developed the 3D Derm Score Assay to reveal the complexities of the skin microenvironment and determine the relationship between critical structures in the epidermis and dermis.

Alpenglow Biosciences sponsors dinner lecture titles “Decoding Immune Exclusion and Tumor Evasion in the TME” during the 2023 annual SITC meeting

Alpenglow Biosciences presents the 3D Spatial Summit, an inaugural event for the field of 3D Spatial Biology to take place on September 21, 2023 in Cambridge, Massachusetts

Alpenglow Biosciences awarded $1.6M grant to develop AI-enabled smart microscopy and 3D database of cancer biopsies

Accelerating Drug Development with AI-Enabled 3D Spatial Biology, an interview with CEO Nicholas Reder and David Alvaro of Pharma’s Almanac

Alpenglow collaborates with Mayo Clinic to accelerate drug development and improve clinical diagnostics.

Alpenglow accelerates progress with key commercial hires including Spatial Biology industry veterans.

Lightspeed Microscopy, Inc., developers of an innovative end-to-end 3D spatial biology platform, has announced today that the company will begin operating under the new name Alpenglow Biosciences, effective immediately.

Lightspeed Microscopy, Inc., an end-to-end 3D pathology platform, announced today it has raised $4 million in a Series A financing round. The round was led by Dynamk Capital and is expected to close with participation from additional investors by mid-July.

NIH Director Dr. Francis Collins posts a blog featuring the early work by CEO Nicholas (Nick) Reder MD MPH, then medical resident in the pathology department at the University of Washington, and Dr. Jonathan Liu of the mechanical engineering department that was inspired by a technical challenge.